DMK Pharmaceuticals Corporation
Other OTCTotal Valuation
DMK Pharmaceuticals Corporation carries a market capitalization of 1,010.00, placing it among publicly traded companies globally. Its enterprise value stands at -6.39M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 1,010.00 |
| Enterprise Value | -6.39M |
Share Statistics
DMK Pharmaceuticals Corporation currently has 10.09M shares outstanding.
| Shares Outstanding | 10.09M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 0.08, and the price-to-book ratio stands at 0.00.
| PE Ratio | N/A |
| PS Ratio | 0.08 |
| PB Ratio | 0.00 |
| P/TBV Ratio | -0.05 |
| P/FCF Ratio | -0.03 |
| P/OCF Ratio | -0.03 |
Enterprise Valuation
| EV / Sales | 3.04 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
DMK Pharmaceuticals Corporation maintains a current ratio of 0.58, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.58 |
| Quick Ratio | 0.50 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | -239.69 |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -210.79 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 5.66 |
Taxes
| Income Tax | 2,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
DMK Pharmaceuticals Corporation's stock has gained approximately 907.14063% over the past 52 weeks. The 50-day moving average sits at 0.00, while the 200-day moving average is 0.00.
| Beta (5Y) | N/A |
| 52-Week Price Change | 907.14063% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, DMK Pharmaceuticals Corporation generated 3.62M in revenue and converted that into -22.23M in net income, yielding earnings per share of -5.37. EBITDA reached -18.16M, while operating income came in at -18.80M.
| Revenue | 3.62M |
| Gross Profit | -1.35M |
| Operating Income | -18.80M |
| Pretax Income | -21.16M |
| Net Income | -22.23M |
| EBITDA | -18.16M |
| EBIT | -18.80M |
| Earnings Per Share (EPS) | -5.37 |
Balance Sheet
Total book value stands at -323.47M, with working capital of -5.59M providing operational flexibility.
| Cash & Cash Equivalents | 6.66M |
| Total Debt | N/A |
| Net Debt | -6.66M |
| Equity (Book Value) | -323.47M |
| Book Value Per Share | -82.10 |
| Working Capital | -5.59M |
Cash Flow
DMK Pharmaceuticals Corporation produced -9.38M in operating cash flow over the past twelve months. After subtracting -91,494.00 in capital expenditures, free cash flow totaled -9.47M - equivalent to -2.40 per share.
| Operating Cash Flow | -9.38M |
| Capital Expenditures | -91,494.00 |
| Free Cash Flow | -9.47M |
| FCF Per Share | -2.40 |
Margins
DMK Pharmaceuticals Corporation operates with a gross margin of -37.30, reflecting its pricing power and cost economics. The operating margin of -519.35 and net profit margin of -614.21 provide insight into operational efficiency.
| Gross Margin | -37.30 |
| Operating Margin | -519.35 |
| Pretax Margin | -584.45 |
| Profit Margin | -614.21 |
| EBITDA Margin | -501.78 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -3,904.47 |
| FCF Yield | -3,391.39 |
Stock Splits
DMK Pharmaceuticals Corporation's most recent stock split took place on May 22, 2023 with a 70:1 split ratio.
| Last Split Date | 5/22/2023 |
| Split Ratio | 70:1 |
Scores
DMK Pharmaceuticals Corporation posts an Altman Z-Score of -57.82, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | -57.82 |